Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes

• US 20040006005A1
• Filed: 07/02/2002
• Published: 01/08/2004
• Est. Priority Date: 07/02/2002
• Status: Abandoned Application

• Current Assignee: ISIS Pharmaceuticals Incorporated
• Original Assignee: ISIS Pharmaceuticals Incorporated
• Inventors: Bhanot, Sanjay
• Application Number:
  US10/188,883
• Publication Number:
  US 20040006005A1
• Time in Patent Office: Days
• US Class Current: 514/8
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C12N 15/1137 against enzymes viral enzymes C12N15/1131; receptors C12N15/1138
• CPC Class Codes: C12N 2310/315 Phosphorothioates
• CPC Class Codes: C12N 2310/321 2'-O-R Modification
• CPC Class Codes: C12N 2310/341 Gapmers, i.e. of the type ===---===
• CPC Class Codes: C12N 2310/346 having a combination of backbone and sugar modifications
• CPC Class Codes: C12N 2310/3521 Methyl
• CPC Class Codes: C12N 2310/3525 MOE, methoxyethoxy
• CPC Class Codes: C12N 9/12 transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

The present invention features methods for treating conditions of insulin resistance, hyperglycemia and/or diabetes. In a broad embodiment, the methods comprise the step of administering to a mammal in need of treatment a therapeutically effective amount of an ILK inhibitor. ILK inhibitors in accordance with the present invention includes small molecules, antibodies, peptides, and antisense compounds. In one embodiment, antisense compounds in accordance with the present invention comprise antisense oligomers.

Claims

1. A method for treating a mammal for insulin resistance, the method comprises administering to the mammal in need of insulin resistance treatment a therapeutically effective amount of an Integrin-linked Kinase inhibitor, thereby treating the mammal for insulin resistance.

2. The method of claim 1 wherein treating includes prophylactically treating.

3. The method of claim 1 wherein the inhibitor specifically binds to and inactivates the Integrin-linked Kinase, the inhibitor is selected from the group consisting of a small molecule, an antibody and a peptide (including a dominant negative peptide).

4. The method of claim 1 wherein the inhibitor is an antisense compound effective to hybridize with and inhibit the nucleic acid molecule expressing Integrin-linked Kinase.

5. The method of claim 1 wherein the inhibitor is an antisense compound selected from the group consisting of a ribozyme, an siRNA, an antisense oligonucleotide, a peptide nucleic acid, a morpholino compound and a locked nucleic acid.

6. The method of claim 1 wherein the inhibitor is an antisense compound comprising about 8 to about 80 nucleobases in length, wherein the antisense compound specifically hybridizes with and inhibits the nucleic acid molecule encoding for the expression of Integrin-linked Kinase.

7. The method of claim 1 wherein the inhibitor comprises an antisense oligonucleotide.

8. A method for treating a mammal for hyperglycemia, the method comprises administering to the mammal in need of treatment thereof a therapeutically effective amount of an Integrin-linked Kinase inhibitor, thereby treating the mammal for hyperglycemia.

9. The method of claim 8 wherein treating includes reducing the mammal'"'"'s blood glucose level.

10. The method of claim 8 wherein treating includes preventing a rise in the mammal'"'"'s blood glucose level.

11. The method of claim 8 wherein the inhibitor specifically binds to and inactivates the Integrin-linked Kinase, the inhibitor is selected from the group consisting of a small molecule, an antibody and a peptide (including a dominant negative peptide).

12. The method of claim 8 wherein the inhibitor is an antisense compound effective to hybridize with and inhibit the nucleic acid molecule expressing Integrin-linked Kinase.

13. The method of claim 8 wherein the inhibitor is an antisense compound selected from the group consisting of a ribozyme, an siRNA, an antisense oligonucleotide, a peptide nucleic acid, a morpholino compound and a locked nucleic acid.

14. The method of claim 8 wherein the inhibitor is an antisense compound comprising about 8 to about 80 nucleobases in length, wherein the antisense compound specifically hybridizes with and inhibits the nucleic acid molecule encoding for the expression of Integrin-linked Kinase.

15. The method of claim 8 wherein the inhibitor comprises an antisense oligonucleotide.

16. A method for treating a mammal for diabetes mellitus, the method comprises administering to the mammal in need of treatment for diabetes a therapeutically effective amount of an Integrin-linked Kinase inhibitor, thereby treating the mammal for diabetes mellitus.

17. The method of claim 16 wherein the diabetes is a type II diabetes.

18. The method of claim 16 wherein the inhibitor specifically binds to and inactivates the Integrin-linked Kinase, the inhibitor is selected from the group consisting of a small molecule, an antibody and a peptide (including a dominant negative peptide).

19. The method of claim 16 wherein the inhibitor is an antisense compound effective to hybridize with and inhibit the nucleic acid molecule expressing Integrin-linked Kinase.

20. The method of claim 16 wherein the inhibitor is an antisense compound selected from the group consisting of a ribozyme, an siRNA, an antisense oligonucleotide, a peptide nucleic acid, a morpholino compound and a locked nucleic acid.

21. The method of claim 16 wherein the inhibitor is an antisense compound comprising about 8 to about 80 nucleobases in length, wherein the antisense compound specifically hybridizes with and inhibits the nucleic acid molecule encoding for the expression of Integrin-linked Kinase.

22. The method of claim 16 wherein the inhibitor comprises an antisense oligonucleotide.